Clinical Trial Update: Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a phase 1/2 study of TROP2 CAR-engineered cord blood-derived NK cells in combination with belzutifan for pancreatic cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Belzutifan (belzutifan)
• TROP2 CAREngineered Cord Blood-Derived NK Cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING